🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. LIBTAYO 350 mg concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%

    phase 3 small molecule active

    1 trial

  2. LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion, Gemcitabine 2 g Powder for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Lacuna Pharma Pty Ltd

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. LIBTAYO 350 mg concentrate for solution for infusion., Vinorelbine 10 mg/ml concentrate for solution for infusion, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, THIO, Gemcitabine 1 g Powder for Solution for Infusion

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. LIBTAYO 350 mg concentrate for solution for infusion., matching Placebo with R2810

    Lacuna Pharma Pty Ltd

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  5. LIOTHYRONINE SODIUM , LEVOTHYROXINE SODIUM , Placebo tablets are white, round, biconvex tablets. The tablets contain no active pharmaceutical ingredient (API), but are manufactured following the manufacturing process of the liothyronine tablets presented in the IMPD for liotyronine 2, 2.5, 3.75, and 5 µg

    Disc Medicine

    Hypothyroidism Triiodothyronine Quality of Life Persistant complaints

    phase 3 small molecule active

    1 trial

  6. LOMUSTINE, 4-L-[131I]iodo-phenylalanine, LOMUSTINE

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 3 small molecule active

    1 trial

  7. LORATADINE , FEXOFENADINE , Dupilumab, Matched placebo to test

    Sanofi-aventis Healthcare Pty Ltd

    Pruritus

    phase 3 small molecule active

    1 trial

  8. LORLATINIB

    Pfizer Australia Pty Ltd

    Advanced ALK positive non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  9. LORLATINIB, AXITINIB, AVELUMAB, AXITINIB, TALAZOPARIB, TALAZOPARIB

    Pfizer Australia Pty Ltd

    Cancer

    phase 3 small molecule active

    1 trial

  10. LOU064, CLINDAMYCIN , Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, LOU064, Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , -

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  11. LOU064, COLESTYRAMINE , TERIFLUNOMIDE, Placebo to teriflunomide 14 mg capsule, hard, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  12. LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, -, -

    Novartis Pharmaceuticals

    Chronic Inducible Urticaria (CINDU)

    phase 3 small molecule active

    1 trial

  13. LOU064, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE , Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, TERIFLUNOMIDE, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  14. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEE)

    phase 3 small molecule active

    1 trial

  15. LPA1 antagonist, LPA1 antagonist, Placebo for BMS-986278

    Bristol-Myers Squibb Australia Pty Ltd

    Idiopathic pulmonary fibrosis

    phase 3 small molecule active

    1 trial

  16. LPA1 antagonist, Placebo for BMS-986278, LPA1 antagonist

    Bristol-Myers Squibb Australia Pty Ltd

    Progressive Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  17. LY2127399

    Eli Lilly and Company

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  18. LY2127399

    Eli Lilly and Company

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  19. LY2189265

    United Therapeutics Europe Ltd

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  20. LY2216684

    Eli Lilly and Company

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  21. LY3819253

    Vir Biotechnology

    Covid19

    phase 3 mab completed

    1 trial

  22. Lactobacillus plantarum IS-10506

    United Therapeutics Europe Ltd

    Constipation - Functional

    phase 3 small molecule completed

    1 trial

  23. Lactose monohydrate, Melatonine Tiofarma 5 mg tabletten

    Disc Medicine

    Chronic low back pain

    phase 3 small molecule active

    1 trial

  24. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen

    NovoThirteen

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources